Key Insights on Gross Profit: Vertex Pharmaceuticals Incorporated vs United Therapeutics Corporation

Vertex vs. United: A Decade of Biotech Profit Growth

__timestampUnited Therapeutics CorporationVertex Pharmaceuticals Incorporated
Wednesday, January 1, 20141162636000519428000
Thursday, January 1, 20151396725000906794000
Friday, January 1, 201615261000001491717000
Sunday, January 1, 201716196000002213533000
Monday, January 1, 201814291000002638058000
Tuesday, January 1, 201913312000003615063000
Wednesday, January 1, 202013752000005469383000
Friday, January 1, 202115630000006670200000
Saturday, January 1, 202217896000007850400000
Sunday, January 1, 202320700000008607000000
Monday, January 1, 20249489600000
Loading chart...

Unleashing insights

A Decade of Growth: Vertex Pharmaceuticals vs. United Therapeutics

In the competitive landscape of biotechnology, Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation have showcased remarkable growth in gross profit over the past decade. From 2014 to 2023, Vertex Pharmaceuticals has seen an impressive increase in gross profit, growing by over 1,500%, from approximately $519 million to $8.6 billion. This surge highlights Vertex's successful expansion and innovation in the pharmaceutical sector.

Conversely, United Therapeutics has demonstrated steady growth, with gross profit rising by nearly 78% during the same period, from $1.16 billion to $2.07 billion. This consistent performance underscores United Therapeutics' resilience and strategic market positioning.

The data reveals a compelling narrative of two companies navigating the complexities of the biotech industry, with Vertex Pharmaceuticals leading in terms of growth rate, while United Therapeutics maintains a stable upward trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025